[1] Torre LA, Bray F, Siegel RL, et al.  Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.   doi: 10.3322/caac.21262
[2] Lu J, Wang W, Zheng C, et al.  Influence of total lymph node count on staging and survival after gastrectomy for gastric cancer: an analysis from a two-institution database in China[J]. Ann Surg Oncol, 2017, 24(2): 486-493.   doi: 10.1245/s10434-016-5494-7

Chen K, Xu XW, Mou YP, et al. Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer[J/OL]. World J Surg Oncol, 2013, 11(1): 182[2018−07−03]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750547/pdf/1477-7819-11-182.pdf. DOI: 10.1186/1477−7819−11−182.

[4] Lee JH, Son SY, Lee CM, et al.  Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy[J]. Gastric Cancer, 2014, 17(3): 529-536.   doi: 10.1007/s10120-013-0306-2
[5] Kang WM, Meng QB, Yu JC, et al.  Factors associated with early recurrence after curative surgery for gastric cancer[J]. World J Gastroenterol, 2015, 21(19): 5934-5940.   doi: 10.3748/wjg.v21.i19.5934
[6] Wu LM, Hu JN, Hua J, et al.  18F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3): 472-480.   doi: 10.1111/j.1440-1746.2011.06919.x
[7] Zou H, Zhao Y.  18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: A meta-analysis[J]. Surg Oncol, 2013, 22(3): 162-166.   doi: 10.1016/j.suronc.2013.05.001

张敬勉, 赵新明, 王建方, 等. 18F-FDG PET/CT显像对胃癌治疗后临床再分期及治疗决策的影响[J].中国全科医学, 2013,16(15): 1360-1365. DOI: 10.3969/j.issn.1007-9572.2013.04.088.

Zhang JM, Zhao XM, Wang JF, et al. Impact of 18F-FDG PET/CT on the Clinical Restaging and Therapeutic Regimens in Post-Treatment Patients with Gastric Carcinoma[J]. Chin Gen Pract, 2013, 16(15): 1360-1365. DOI: 10.3969/j.issn.1007-9572.2013.04.088.

[9] Ajanj JA, Barthel JS, Bekaii-Saab T, et al.  Gastric cancer[J]. J Natl Compr Canc Netw, 2010, 8(4): 378-409.   doi: 10.6004/jnccn.2010.0030
[10] Wu CX, Zhu ZH.  Diagnosis and evaluation of gastric cancer by positron emission tomography[J]. World J Gastroenterol, 2014, 20(16): 4574-4585.   doi: 10.3748/wjg.v20.i16.4574
[11] Ozkan E, Araz M, Soydal C, et al.  The role of 18F-FDG-PET/CT in the preoperative staging and posttherapy follow up of gastriccancer: Comparison with spiral CT[J]. World J Surg Oncol, 2011, 9(1): 75-.   doi: 10.1186/1477-7819-9-75
[12] Bilici A, Ustaalioglu BB, Seker M, et al.  The role of 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?[J]. Eur J Nucl Med Mol Imaging, 2011, 38(1): 64-73.   doi: 10.1007/s00259-010-1611-1
[13] Lee JW, Lee SM, Lee MS, et al.  Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9): 1425-1434.   doi: 10.1007/s00259-012-2164-2
[14] Sharma P, Singh H, Suman SK, et al.  18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population[J]. Nucl Med Commun, 2012, 33(9): 960-966.   doi: 10.1097/MNM.0b013e328355b694
[15] Kawanaka Y, Kitajima K, Fukushima K, et al.  Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT[J]. Eur J Radiol, 2016, 85(5): 989-995.   doi: 10.1016/j.ejrad.2016.03.003